MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

Hutchison China MediTech Ltd ADR

Slēgts

SektorsVeselības aprūpe

15.96 0.25

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

15.94

Max

16.03

Galvenie mērījumi

By Trading Economics

Ienākumi

6M

Pārdošana

162M

P/E

Sektora vidējais

77.1

39.564

Peļņas marža

3.676

Darbinieki

1,811

EBITDA

-5M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+18.89% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

2.7B

Iepriekšējā atvēršanas cena

15.71

Iepriekšējā slēgšanas cena

15.96

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

Hutchison China MediTech Ltd ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 11. jūl. 22:19 UTC

Iegādes, apvienošanās, pārņemšana

FCC Approves U.S. Cellular Sale to T-Mobile

2025. g. 11. jūl. 17:28 UTC

Galvenie tirgus virzītāji

SharpLink Gaming Gains on Ethereum Purchase

2025. g. 11. jūl. 16:57 UTC

Peļņas

BASF Cuts Outlook on Global Economy Uncertainty

2025. g. 12. jūl. 17:01 UTC

Peļņas

That's a Wrap on Prime Day. What the Numbers Show. -- Barrons.com

2025. g. 12. jūl. 14:53 UTC

Peļņas

That's a Wrap on Prime Day. What the Numbers Show. -- Barrons.com

2025. g. 12. jūl. 02:24 UTC

Iegādes, apvienošanās, pārņemšana

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- Update

2025. g. 12. jūl. 02:05 UTC

Iegādes, apvienošanās, pārņemšana

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- WSJ

2025. g. 12. jūl. 02:05 UTC

Iegādes, apvienošanās, pārņemšana

Google to Hire Windsurf CEO and Other Employees, Company Says -- WSJ

2025. g. 12. jūl. 02:05 UTC

Iegādes, apvienošanās, pārņemšana

Google to Pay About $2.4 Billion in Deal to License Tech of AI Coding Startup, Sources Say -- WSJ

2025. g. 11. jūl. 21:45 UTC

Tirgus saruna

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

2025. g. 11. jūl. 19:46 UTC

Iegādes, apvienošanās, pārņemšana

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

2025. g. 11. jūl. 19:45 UTC

Tirgus saruna

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

2025. g. 11. jūl. 19:05 UTC

Tirgus saruna

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

2025. g. 11. jūl. 18:18 UTC

Tirgus saruna

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

2025. g. 11. jūl. 17:35 UTC

Tirgus saruna

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

2025. g. 11. jūl. 17:26 UTC

Tirgus saruna

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

2025. g. 11. jūl. 16:53 UTC

Tirgus saruna

Crude Futures Add to Early Gains -- Market Talk

2025. g. 11. jūl. 16:42 UTC

Peļņas

BASF Cuts Outlook on Global Economic Uncertainty

2025. g. 11. jūl. 16:08 UTC

Tirgus saruna

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

2025. g. 11. jūl. 16:05 UTC

Peļņas

BASF Will Publish Half-Year Results on July 30

2025. g. 11. jūl. 16:04 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 11. jūl. 16:04 UTC

Tirgus saruna

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

2025. g. 11. jūl. 16:03 UTC

Peļņas

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

2025. g. 11. jūl. 16:02 UTC

Peļņas

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

2025. g. 11. jūl. 16:01 UTC

Peļņas

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

2025. g. 11. jūl. 16:00 UTC

Peļņas

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

2025. g. 11. jūl. 15:59 UTC

Peļņas

BASF Cuts 2025 Earnings View

2025. g. 11. jūl. 15:58 UTC

Peļņas

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

2025. g. 11. jūl. 15:57 UTC

Peļņas

BASF 2Q EBIT Before Special Items EUR810M

2025. g. 11. jūl. 15:54 UTC

Peļņas

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

Salīdzinājums

Cenas izmaiņa

Hutchison China MediTech Ltd ADR Prognoze

Cenas mērķis

By TipRanks

18.89% augšup

Prognoze 12 mēnešiem

Vidējais 19.07 USD  18.89%

Augstākais 27 USD

Zemākais 14.7 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Hutchison China MediTech Ltd ADR — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

3 ratings

1

Pirkt

2

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

14.24 / 14.78Atbalsts un pretestība

Īstermiņā

Strong Bearish Evidence

Vidējā termiņā

Weak Bearish Evidence

Ilgtermiņā

Weak Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.